The recommendations are learnt to have been approved by the DCGI. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. Govt Panel Recommends Against Allowing SII to Conduct Trial of Covovax on Children Aged 2-17 Yrs
The recommendations are learnt to have been approved by the DCGI. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. Govt Panel Recommends Against Allowing SII to Conduct Trial of Covovax on Children Aged 2-17 Yrs
No comments:
Post a Comment